Kulkarni, 2019 - Google Patents
Outcome after spontaneous remission in children with nephrotic syndrome relapse treated with stress dose of steroids and if required antibioticsKulkarni, 2019
- Document ID
- 10779949111480291788
- Author
- Kulkarni V
- Publication year
- Publication venue
- PQDT-Global
External Links
Snippet
Background/Objectives-Prevalence of Nephrotic syndrome is 20-40 million worldwide. Although 80% children undergo remission within 4 weeks of corticosteroid therapy after their initial episode, many children will have relapses that may be frequent or infrequent. These …
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sarantopoulos et al. | How I treat refractory chronic graft-versus-host disease | |
| Soussain et al. | Primary vitreoretinal lymphoma: a diagnostic and management challenge | |
| US20240025975A1 (en) | Administration of anti-c5 antibodies for treatment of patients with membranoproliferative glomerulonephritis | |
| Zandbelt et al. | Etanercept in the treatment of patients with primary Sjögren's syndrome: a pilot study. | |
| Spagnolo et al. | Non‐steroid agents for idiopathic pulmonary fibrosis | |
| Mounier et al. | AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy | |
| JP2023134842A (en) | Pharmaceutical composition for preventing and/or treating atopic dermatitis, containing an IL-31 antagonist as an active ingredient | |
| US20220151581A1 (en) | Methods for treating idiopathic pulmonary fibrosis | |
| CN111163767A (en) | Treatment options for paroxysmal nocturnal hemoglobinuria | |
| JP6799831B1 (en) | A pharmaceutical composition for the prevention and / or treatment of pruritus dialysis containing an IL-31 antagonist as an active ingredient. | |
| Roccatello et al. | Refractory systemic lupus erythematosus: identification and pharmacological management | |
| Kulkarni | Outcome after spontaneous remission in children with nephrotic syndrome relapse treated with stress dose of steroids and if required antibiotics | |
| JPWO2016167263A1 (en) | A pharmaceutical composition for preventing and / or treating atopic dermatitis, comprising an IL-31 antagonist as an active ingredient | |
| CN111886249A (en) | Screening method for identifying and treating HIV-1 infected patient subpopulations suitable for long-term anti-CCR 5 agent treatment | |
| US20240307383A1 (en) | Combination of zibotentan and dapagliflozin for the treatment of proteinuria chronic kidney disease | |
| JP2025537802A (en) | Methods for treating or preventing transthyretin-mediated amyloidosis | |
| TW202337443A (en) | Methods of treating sjogren’s syndrome or mixed connective tissue disease using a tlr7/8 antagonist | |
| Cohen et al. | Safety, tolerability, pharmacokinetic and pharmacodynamic properties of SBI-087, a CD20-directed B-cell depleting agent: Phase 1 dose escalating studies in patients with either mild rheumatoid arthritis or systemic lupus | |
| TWI871349B (en) | Pharmaceutical composition for the prevention and/or treatment of dialysis pruritus containing IL-31 antagonist as an active ingredient | |
| EP4247382A1 (en) | Methods of treating systemic lupus erythematosus using btk inhibitors | |
| JP7417339B1 (en) | Treatment of adenovirus infection or diseases associated with adenovirus infection | |
| Skrifvars et al. | Granulomatous glomerulonephritis in a patient with rheumatoid arthritis treated with gold salts | |
| Stewart et al. | Amiodarone pneumonitis | |
| WO2025210517A1 (en) | Humanized anti-cd40 antibodies for treating sjögren's disease | |
| CN117940161A (en) | Eanelizumab and methods of use thereof in the treatment or prevention of IgG 4-related diseases |